New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
06:27 EDTICE, TROW, RYNYSE, others seek to end 'maker-taker' rebate system, Bloomberg reports
The New York Stock Exchange (ICE) and a number of money managers have been lobbying the SEC to do away with the practice of paying rebates to large brokers to attract trades to stock exchanges and other trading platforms, sources say, reports Bloomberg. The rebate system is known as “maker-taker.” Other firms that attended meetings with SEC commissioners included T. Rowe Price Group (TROW), Royal Bank of Canada (RY) and IEX Group Inc., sources added. Reference Link
News For ICE;TROW;RY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
19:30 EDTRYRoyal Bank of Canada prop desk spin-off plan shot down by regulators, WSJ says
Royal Bank of Canada has dropped a plan to spin off a profitable proprietary trading desk business into a hedge fund after U.S. regulators rejected the plan, The Wall Street Journal reports, citing people familiar with the matter. Executives at the bank had approved the plan to invest as much as $1B into a hedge fund managed by some of the company's top New York proprietary traders, one of the people added. The SEC and Federal Reserve denied the plan "late in the game," The Wall Street Journal said, citing a person familiar with the negotiations. Reference Link
06:03 EDTICEIntercontinentalExchange completes 1st phase of transition to ICE Futures Europe
Subscribe for More Information
September 26, 2014
16:18 EDTTROWT. Rowe urges Allergan to drop bid for Salix, has 'growing concern', FT says
T. Rowe Price (TROW), the third largest shareholder of Allergan (AGN), has urged the company to not partake in any acquisitions that would thwart Valeant's (VRX) hostile takeover plan, The Financial Times reports, citing senior business correspondent David Crow. Allergan is currently mulling the possibility of acquiring Salix Pharmaceuticals (SLXP), which may effectively squash Valeant's potential hostile takeover of Allergan. T. Rowe Price said in a statement, "Over the past several months, we have been watching with growing concern the corporate governance practices of the Allergan board. In our view, the issues to be voted on at the special meeting of shareholders on December 18 are of such importance that they impose a special duty on the board to refrain from approving any significant, irreversible commitments by the company between now and then unless shareholders are offered the opportunity to vote on them. We believe this should apply even in the event of all-cash acquisitions that do not ordinarily require a shareholder vote." Reference Link
September 24, 2014
09:08 EDTICEIntercontinentalExchange Trade Vault approved by Ontario Securities Commission
Subscribe for More Information
September 22, 2014
08:51 EDTTROWT. Rowe Price should be owned into Q4, says Bernstein
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use